CORRECTIONS

Author Corrections

The September 1, 2009 article by Anguiano et al, entitled, “Gene Expression Profiles of Tumor Biology Provide a Novel Approach to Prognosis and May Guide the Selection of Therapeutic Targets in Multiple Myeloma” (J Clin Oncol 27:4197-4203, 2009), contained omissions that were brought to our attention by a reader.

In the Authors’ Disclosures of Potential Conflicts of Interest section, the following disclosures should have been made:

Consultant or Advisory Role: Cristina Gasparetto, Celgene (C), Millennium Pharmaceuticals (C); Bart Barlogie, Celgene (C), Genzyme (C), Millennium Pharmaceuticals (C); John D. Shaughnessy Jr, Celgene (C), Genzyme (C), Myeloma Health (C), Novartis (C).

Stock Ownership: John D. Shaughnessy Jr, Myeloma Health.

Honoraria: Cristina Gasparetto, Celgene, Millennium Pharmaceuticals; Bart Barlogie, Celgene, Millennium Pharmaceuticals; John D. Shaughnessy Jr, Celgene, Genzyme, Myeloma Health, Novartis.

Research Funding: Cristina Gasparetto, Celgene, Cephalon; Bart Barlogie, Celgene, Millennium Pharmaceuticals, Novartis.

Other Remuneration: Bart Barlogie, Celgene, Millennium Pharmaceuticals.

The authors apologize for the oversight.

DOI: 10.1200/JCO.2012.43.0991; published April 20, 2012

The June 10, 2011 editorial by Bezjak, entitled, “Harnessing Radiation Technology to Improve Survival” (J Clin Oncol 29:2295-2296, 2011), contained an error.

In the fourth sentence of the third paragraph, the *P* value for patients who underwent computed tomography (CT) simulation was given as $P < .1$, whereas it should have been $P < .01$, as follows:

“Even when controlling for the known clinical and demographic variables, as well as for comorbidity and

other treatment received, patients who underwent CT simulation to plan their thoracic radiation had a significant reduction in the risk of death (HR, 0.77; $P < .01$) when compared with those whose thoracic radiation was traditionally planned.”

The author apologizes for the mistake.

DOI: 10.1200/JCO.2012.43.1023; published April 20, 2012

The October 10, 2011 ASCO special article by Griggs et al, entitled, “American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women With Early-Stage Invasive Breast Cancer” (J Clin Oncol 29:3939-3942, 2011), contained errors.

In Table 1, all content in the first and third rows should have been omitted. In the second-to-last row, the acronym

“SOFT Trial” should have been included at the end of the trial name, as follows:

“Suppression of ovarian function plus either tamoxifen or exemestane compared with tamoxifen alone in treating premenopausal women with hormone-responsive breast cancer (SOFT Trial).”

The online version has been corrected in departure from the print. The authors apologize for the mistakes.

DOI: 10.1200/JCO.2012.43.1031; published April 20, 2012